The effect of lifestyle changes in non-alcoholic fatty liver disease

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 267-273

  Centis, Elena ^a   Marzocchi, Rebecca ^a   Di Domizio, Silvia ^a   Ciaravella, Maria Francesca ^a   Marchesini, Giulio ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diet; Exercise; Lifestyle; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; TETRAHYDROLIPSTATIN;

BEHAVIOR THERAPY; CALORIC INTAKE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; EATING HABIT; EXERCISE; HEPATITIS; HISTOPATHOLOGY; HUMAN; LIFESTYLE MODIFICATION; LIPOGENESIS; LIVER BIOPSY; LIVER NECROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

BEHAVIOR THERAPY; COUNSELING; DIET, REDUCING; EXERCISE; FATTY LIVER; HEALTH BEHAVIOR; HUMANS; RISK REDUCTION BEHAVIOR;

EID: 77952574249     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282101     Document Type: Review

References (65)

1. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
2. Adams LA, Lymp JF, St Sauver J, et al: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
3. Marchesini G, Bugianesi E, Forlani G, et al: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923.
4. Adams LA, Sanderson S, Lindor KD, Angulo P: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138.
5. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD: Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;41:943-949.
6. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-728.
7. Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, et al: Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-2175.
8. Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV: Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005;28:1222-1224.
9. Browning JD, Szczepaniak LS, Dobbins R, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
10. Szczepaniak LS, Nurenberg P, Leonard D, et al: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-E468.
11. Bellentani S, Saccoccio G, Masutti F, et al: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.
12. Capristo E, Miele L, Forgione A, Vero V, Farnetti S, Mingrone G, et al: Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005;9:265-268.
13. Reinehr T, Schmidt C, Toschke AM, Andler W: Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 2009;94:437-442.
14. Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725.
15. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-1413.
16. Sato F, Tamura Y, Watada H, et al: Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 2007;92:3326-3329.
17. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al: One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-1081.
18. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, et al: Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73-79.
19. Andersen T, Gluud C, Franzmann MB, Christoffersen P: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-229.
20. Zivkovic AM, German JB, Sanyal AJ: Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007;86:285-300.
21. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al: Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008;48:993-999.
22. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA: Severe NAFLD with hepatic necroinflammatory changes in mice fed trans-fats and a high fructose corn syrup equivalent. Am J Physiol 2008;295: G987-G995.
23. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351.
24. Harrison SA, Neuschwander-Tetri BA: Pharmacologic management of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:715-728, xii.
25. Musso G, Gambino R, De Michieli F, et al: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-916.
26. Westerbacka J, Lammi K, Hakkinen AM, et al: Dietary fat content modifies liver fat in overweight non-diabetic subjects. J Clin Endocrinol Metab 2005;90:2804-2809.
27. Franz MJ, VanWormer JJ, Crain AL, et al: Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755-1767.
28. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al: Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008;48:1791-1798.
29. Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
30. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN: Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 2006;130:2023-2030.
31. Perseghin G, Lattuada G, De Cobelli F, et al: Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 2007;30:683-688.
32. Farrell SW, Cheng YJ, Blair SN: Prevalence of the metabolic syndrome across cardiorespiratory fitness levels in women. Obes Res 2004;12:824-830.
33. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN: Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome. A prospective study of men and women. Circulation 2005;112:505-512.
34. Bassuk SS, Manson JE: Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005;99:1193-1204.
35. Perseghin G, Price TB, Petersen KF, et al: Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996;335:1357-1362.
36. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ: Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001;286:1218-1227.
37. Goodyear LJ, Kahn BB: Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998;49:235-261.
38. Hannukainen JC, Nuutila P, Borra R, et al: Increased physical activity decreases hepatic free fatty acid uptake: a study in human monozygotic twins. J Physiol 2007;578:347-358.
39. Lavoie JM, Gauthier MS: Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sci 2006;63:1393-1409.
40. Hickman IE, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, et al: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-419.
41. Ueno T, Sugawara H, Sujaku K, et al: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107.
42. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J: Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50:68-76.
43. Sreenivasa Baba C, Alexander G, Kalyani B, et al: Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006;21:191-198.
44. Johnson NA, Sachinwalla T, Walton DW, et al: Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-1112.
45. Ibanez J, Izquierdo M, Arguelles I, et al: Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 2005;28:662-667.
46. Ballor DL, Keesey RE: A meta-analysis of the factors affecting exercise-induced changes in body mass, fat mass and fat-free mass in ma les and females. Int J Obes 1991;15:717-726.
47. Williams MA, Haskell WL, Ades PA, et al: Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2007;116:572-584.
48. Wadden TA, Butryn ML: Behavioral treatment of obesity. Endocrinol Metab Clin North Am 2003;32: 981-10 03, x.
49. Wing RR: Behavioral approaches to the treatment of obesity;in Bray GA, Bouchard C (eds): Handbook of Obesity: Clinical Applications, ed 2. New York, Marcel Dekker Inc., 2004, pp 147-167.
50. Marchesini G, Suppini A, Forlani G: NAFLD treatment: cognitive-behavioral therapy has entered the arena. J Hepatol 2005;43:926-928.
51. Renjilian DA, Perri MG, Nezu AM, Mc-Kelvey WF, Shermer RL, Anton SD: Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. J Consult Clin Psychol 2001;69:717-721.
52. Miltenberger RG: Behavior Modification: Principle and Procedures. Pacific Grove, Brooke/Cole Publishing Co., 1994.
53. Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT: Understanding and preventing relapse. Am Psychol 1986;41:765-782.
54. Perri MG, Corsica JA: Improving the maintenance of weight lost in behavioral treatment of obesity;in Wadden TA, Stunkard AJ (eds): Handbook of Obesity Treatment. New York, The Guildford Press, 2002, pp 357-379.
55. Wing RR: Behavioral weight control;in Wadden TA, Stunkard AJ (eds): Handbook of Obesity Treatment. New York, The Guildford Press, 2002, pp 301-316.
56. Wadden TA, Butryn ML, Wilson C: Lifestyle modification for the management of obesity. Gastroenterology 2007;132:2226-2238.
57. Jakicic JM, Clark K, Coleman E, et al: American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2001;33:2145-2156.
58. Lichtenstein AH, Appel LJ, Brands M, et al: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96.
59. Bellentani S, Dalle Grave R, Suppini A, Marchesini G: Behavior therapy in nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008;47:746-754.
60. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-419.
61. Zelber-Sagi S, Kessler A, Brazowsky E, et al: A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-644.
62. Osland EJ, Powell EE, Banks M, Jonsson JR, Hickman IJ: Obesity management in liver clinics: translation of research into clinical practice. J Gastroenterol Hepatol 2007;22:504-509.
63. Marchesini G, Trovati M: Type 2 diabetes and the Naaman syndrome. Diabetes Care 2003;26:3195.
64. Suzuki A, Lindor K, St Sauver J, et al: Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43:1060-1066.
65. Thomas EL, Brynes AE, Hamilton G, et al: Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006;12:5813-5819.